107 related articles for article (PubMed ID: 30095971)
1. Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis.
Cai X; Gao X; Yang W; Ji L
Diabetes Technol Ther; 2018 Oct; 20(10):704-714. PubMed ID: 30095971
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
Gao W; Wang Q; Yu S
J Endocrinol Invest; 2016 Sep; 39(9):1061-74. PubMed ID: 27072669
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
7. The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.
Liu X; Xiao Q; Zhang L; Yang Q; Liu X; Xu L; Cheng W
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):687-98. PubMed ID: 24639059
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
Wang B; Sun Y; Sang Y; Liu X; Liang J
Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
[TBL] [Abstract][Full Text] [Related]
11. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
13. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
14. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X; Wang H; Jing Z; Fu P
Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
[TBL] [Abstract][Full Text] [Related]
15. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Łopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Foroutan N; Muratov S; Levine M
Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
[TBL] [Abstract][Full Text] [Related]
17. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
18. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
